Vestor Capital LLC increased its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 183.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,238 shares of the medical technology company’s stock after purchasing an additional 2,096 shares during the period. Vestor Capital LLC’s holdings in Stryker were worth $892,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC increased its stake in Stryker by 1,432.8% in the third quarter. International Assets Investment Management LLC now owns 25,000 shares of the medical technology company’s stock valued at $6,885,000 after purchasing an additional 23,369 shares in the last quarter. Amundi boosted its position in shares of Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after purchasing an additional 192,447 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Stryker by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after purchasing an additional 65,333 shares in the last quarter. Veritas Asset Management LLP acquired a new position in shares of Stryker in the 2nd quarter valued at $168,057,000. Finally, Bank of America Corp DE acquired a new position in shares of Stryker in the 2nd quarter valued at $1,404,284,000. Institutional investors own 77.09% of the company’s stock.
Stryker Trading Down 0.1%
SYK opened at $325.69 on Tuesday. The stock has a market capitalization of $123.99 billion, a P/E ratio of 34.69, a P/E/G ratio of 2.33 and a beta of 0.78. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The firm’s fifty day simple moving average is $292.26 and its 200 day simple moving average is $323.41. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.
Analyst Upgrades and Downgrades
SYK has been the topic of several research analyst reports. Wells Fargo & Company dropped their price objective on Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. JPMorgan Chase & Co. decreased their target price on Stryker from $350.00 to $340.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Robert W. Baird lowered their price target on Stryker from $385.00 to $334.00 in a report on Friday, October 30th. Jefferies Financial Group dropped their price target on Stryker from $440.00 to $405.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Finally, Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $342.19.
View Our Latest Research Report on SYK
Insider Transactions at Stryker
In other news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 901,267 shares of company stock valued at $297,123,701 over the last three months. Company insiders own 4.60% of the company’s stock.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.
The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Founded in 1941 by orthopedic surgeon Dr.
Recommended Stories
- Five stocks we like better than Stryker
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
